The disclosure provides fusion proteins specific for both CD137 and PD-L1, which fusion protein can be used to co-stimulate lymphocyte activation in a PD-L1-target-dependent manner. Such fusion proteins can be used in many pharmaceutical applications, for example, as anti-cancer agents and/or immune modulators for the treatment or prevention of human diseases such as a variety of tumors. The present disclosure also concerns methods of making the fusion proteins described herein as well as compositions comprising such fusion proteins. The present disclosure further relates to nucleic acid molecules encoding such fusion proteins and to methods for generation of such fusion proteins and nucleic acid molecules. In addition, the application discloses therapeutic and/or diagnostic uses of such fusion proteins as well as compositions comprising one or more of such fusion proteins.本發明提供CD137與PD-L1兩者之特異性融合蛋白，該融合蛋白可用於以PD-L1標靶依賴性方式共同刺激淋巴細胞活化。此融合蛋白可在許多醫藥應用中使用，舉例而言，作為抗癌劑及/或免疫調節劑，用於治療或預防人類疾病，如許多類的腫瘤。本發明亦有關製備本文所述融合蛋白以及包含此類融合蛋白之組合物的方法。本發明進一步有關編碼此類融合蛋白的核酸分子，以及有關用於產生此類融合蛋白與核酸分子的方法。此外，本申請案揭示此類融合蛋白以及包含一或多個此類融合蛋白之組合物的治療及/或診斷用途。
